Literature DB >> 7447407

Ampicillin therapy of experimental enterococcal endocarditis.

R R Tight.   

Abstract

In rabbits with experimental enterococcal endocarditis, subcutaneously implanted perforated polyethylene chambers were used for ampicillin administration by intra-chamber injection. A total of 21 days of intra-chamber ampicillin therapy sterilized vegetations of 14 out of 14 rabbits with experimental enterococcal endocarditis. In rabbits treated for less than 21 days, the duration of therapy and quantitative vegetation cultures were inversely related. Peak serum minimal bactericidal titers were greater than or equal to 1:8 in 94% of the determinations. Trough serum minimal bactericidal titers were less than or equal to 1:2. The mean trough serum ampicillin concentration (2.6 micrograms/ml) was greater than the minimal bactericidal concentration of ampicillin for the infecting enterococcus and less than the mean trough chamber fluid ampicillin concentration (3.7 micrograms/ml). Relatively prolonged therapy with intrachamber injections seemed to be well tolerated. Combination drug therapy of enterococcal endocarditis may not always be required. The maintenance of serum minimal bactericidal titers greater than or equal to 1:8 throughout the therapy of endocarditis, as is often recommended, may be unnecessary.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7447407      PMCID: PMC283988          DOI: 10.1128/AAC.18.2.307

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Fluid and penicillin G dynamics in polyethylene chambers implanted subcutaneously in rabbits.

Authors:  R R Tight; R B Prior; R L Perkins; C A Rotilie
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

2.  Cephalosporin-aminoglycoside synergism in experimental enterococcal endocarditis.

Authors:  A J Weinstein; A L Lentnek
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Concentration of antibacterial agents in interstitial tissue fluid.

Authors:  G D Chisholm; P M Waterworth; J S Calnan; L P Garrod
Journal:  Br Med J       Date:  1973-03-10

4.  Experimental clindamycin-associated colitis in rabbits. Evidence of toxin-mediated mucosal damage.

Authors:  L Katz; J T LaMont; J S Trier; E B Sonnenblick; S W Rothman; S A Broitman; S Rieth
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

5.  Ampicillin in the treatment of enterococcal endocarditis.

Authors:  H N Beaty; M Turck; R G Petersdorf
Journal:  Ann Intern Med       Date:  1966-10       Impact factor: 25.391

6.  Antimicrobial therapy of experimental enterococcal endocarditis.

Authors:  E W Hook; R B Roberts; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

7.  Enterococcal endocarditis in heroin addicts.

Authors:  N E Reiner; K V Gopalakrishna; P I Lerner
Journal:  JAMA       Date:  1976-04-26       Impact factor: 56.272

8.  Serum and subcutaneous chamber fluid dynamics of penicillins after single large parenteral doses.

Authors:  R R Tight; A C White
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

  8 in total
  10 in total

Review 1.  Serum bactericidal test.

Authors:  C W Stratton
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 2.  Standardization of the serum bactericidal test and its relationship to levels of antimicrobial agents.

Authors:  C W Stratton
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 3.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 4.  Virulence of enterococci.

Authors:  B D Jett; M M Huycke; M S Gilmore
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

5.  Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors:  D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  In vitro response to bactericidal activity of cell wall-active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics.

Authors:  R Fontana; A Grossato; M Ligozzi; E A Tonin
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 7.  Therapy of enterococcal infections.

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

8.  Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.

Authors:  C Thauvin; G M Eliopoulos; S Willey; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Aortic endocarditis caused by gentamicin-resistant Enterococcus faecalis.

Authors:  M L Fernández-Guerrero; C Barros; J L Rodriguez Tudela; R Fernández Roblas; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

10.  Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

Authors:  W C Hellinger; M S Rouse; P M Rabadan; N K Henry; J M Steckelberg; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.